News-Medical.Net January 31, 2025
Australian cancer researchers are the first to establish a next-generation gene-editing tool for modeling and interrogating human disease.
A novel pre-clinical model expressing an enhanced version of a new genome-engineering enzyme called Cas12a was generated by researchers at the Olivia Newton-John Cancer Research Institute (ONJCRI), WEHI and Genentech, a member of the Roche Group.
Cas enzymes are required to cut specific sections of DNA or RNA during CRISPR experiments. CRISPR is a revolutionary gene-editing tool widely used for cancer research, which is currently in the early stages of clinical application in patients.
The researchers were also able to identify genes that led to accelerated lymphoma growth in the pre-clinical model by using unique Cas12a-compatible mouse whole-genome CRISPR “libraries”.
This new...
Today's Sponsors
Today's Sponsor